Genetic Analysis Of The Plasminogen And Coagulation System In Mice

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 132-153

  Carmeliet, Peter ^a   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Adenovirus; Coagulation system; Fibrinolysis; Gene therapy; Plasminogen system; Transgenic mice

Indexed keywords

PLASMINOGEN;

ADENOVIRUS; ANIMAL MODEL; BLOOD CLOTTING; CONFERENCE PAPER; FIBRINOLYSIS; GENE THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ARTERIOSCLEROSIS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD VESSELS; EMBRYONIC AND FETAL DEVELOPMENT; ENZYME ACTIVATION; FIBRINOLYSIS; GENE TARGETING; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT FUSION PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION; WOUND HEALING;

EID: 0029854422     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217292     Document Type: Article

References (106)

1. Edgington TS. Mackman N, Brand K & Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
2. Furie B & Furic BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
3. Davie E. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
4. Esmon CT. The protein C anticoagulant pathway. Arteriosclerosis and thrombosis 1992: 12: 135-145.
5. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gin mutation in factor V a a pathogenic risk factor for thrombosis. Thromb Haemost 1995: 74: 139-148.
6. Bick RL & Pegram M. Syndromes of hypercoagulability and thrombosis: a review. Seminars Thromb Hemost 1994; 20: 109-132.
7. Broze, GJ. Tissue factor pathway inhibitor and the revised hypothesis of blood coagulation. Trends Cardiovasc. Medicine 1992; 2: 72-77.
8. Hoyer LW. Hemophila A. N Engl J Med 1996:330: 38-47.
9. Bolton-Maggs PHB & Hill FGH. The rarer inherited coagulation disorders: a review. Blood Reviews 1995; 9:65-76.
10. Altieri, D.C. Xa receptor EPR-1. FASEB J. 9. 860-865 (1995).
11. Coughlin, S.R. Molecular mechanisms of thrombin signaling. Semin. Hematology 1994: 31. 270-277.
12. Astrup T.In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol 3 (Davidson JF. Rowan RM, Samama MM. Desnoyers PC. eds.). Raven Press, New York. 1978; pp 1-57.
13. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991: 78: 3114-3124.
14. Vassalli JD. Sappino JD. Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991:88: 1067-1072.
15. Schneiderman J. Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991; 1: 99-102.
16. Wiman B. Plasminogen activator inhibitor 1 in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
17. Lawrence DA & Ginsburg D. (1995) In Plasminogen Activator Inhibitors, eds High KA & Roberts HR (Dekker. New York), 256: 517-543.
18. Bachmann F. The engima of PA1-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 1995; 74: 172-179.
19. Martin TJ. Allan EH. Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regulation 1993; 3:209-214.
20. Hajjar, K.A. Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995:74. 294-301.
21. Plow, E.F. Herrcn, T. Redlitz, A. Miles, L.A. and Hoover-Plow, J.L. The cell biology of the plasminogen system. FASEB J. 1995:9, 939-945.
22. Vassalli JD. The Urokinase Receptor. Fibrinolysis 1994; 8 (Suppl 1): 172-181.
23. Blasi, F. Conese, M. Moller, L.B. Pedersen, N. Cavallaro, U. Cubellis, M.V. Fazioli, F. Hcrnandez-Marrero, L. Limongi, P. Munoz-Canoves, P. Resnati, M. Riittininen, L. Sidcnius, N. Soravia, E. Soria, M.R. Stoppelli, M.P. Talarico, D. Teesalu, T. and Valcamonica. S. The urokinase receptor: structure, regulation and inhibitor-mediated internalization. Fibrinolysis 1994;8, suppl. 1: 182-188.
24. Dano, K. Behrendt, N. Brunner, N. Ellis, V. Ploug, M. and Pyke, C. The urokinase-receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8, Suppl. 1: 189-203.
25. Wei, Y. Waltz, D.A. Rao, N. Drummond, R.J. Rosenberg, S. and Chapman, H.A.Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chent 1994:269: 32380-32388.
26. Saksela, O. & Rifkin, D. Cell-associated plasminogen activation: regulation and physiological functions. A Rev Cell Biol 1988; 4: 93-126.
27. Andreasen PA, Sottrup-Jensen LI et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Letters 1994; 338: 239-245.
28. Capecchi MR. Targeted gene replacement. Scientif. American 1994; 34-41.
29. Nagy A. Engineering the mouse genome. Methods Enzymol (in press).
30. Nagy A & Rossant J. Targeted mutagenesis: analysis of phenotype without germline transmission. J. Clin Invest 1996; 6: 1360-1365.
31. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A. Harpal K. Eberhardt C, Declercq C. Pawling J. Moons L. Collen D. Risau W & Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
32. Mulligan RCM. The basic science of gene therapy. Science 1993; 260: 926-932.
33. Schneider MD & French BA. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation 1995: 88: 1937-1942.
34. Carmeliet P. Stassen JM. Collen D, Meidell R and Gerard R. Adenovirus-mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice, (submitted)
35. Soifer SJ. Peters KG. O'Keefe J & Coughlin SR. Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 1994; 144:60-69.
36. Luther T, Flôssel C, Mackman N, Bierhaus A, Kasper M, Albrecht S, Sage HA, Iruela-Arispe L, Grossman H, Strôhlein A, Zhang Y, Nawroth PP, Carmeliet P, Loskutoff DJ & Millier M. Tissue factor expression during human and mouse development. Am J Pathol 1996: in press.
37. Imada S, Yamaguchi H, Nagumo N. Katyanagi S, Iwasaki H & Imada M. Identification of feto-modulin, a surface marker protein of fetal development as thrombomodulin by gene gene cloning and functional assays. Dev Biol 1990; 140: 113-122.
38. Healy A, Rayburn H. Rosenberg R & Weiler H. Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 1995; 92:850-854.
39. Carmeliet P, Mackman N, Moons L, Luther T, Gressens P., Van Vlaenderen I, Demunck H, Kasper M., Breier G., Evrard P., Müller M., Risau W, Edgington T & Collen D., Role of the cellular receptor tissue factor in embyonic vessel development., (Nature, in press).
40. Sato Y. Asada Y. Marutsuka K. Hatakeyam K & Sumiyoshi A. Thromb Haemost 1996,75: 389-392.
41. Rottingcn JA, Endcn T, Camerer E. Iversen JG & Prydz H. J Biol Chem 1995. 270:4650-4660.
42. Connolly AJ, Ishihara H, Kahn ML, Farese Jr RV & Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996: 381: 516-519.
43. Suh TT. Holmback K, Jensen NJ, Daugherty CC, Small K, Simon DI. Potter SS & Degen JL. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen deficient mice. Genes & Development 1995; 9: 2020-2033.
44. Erickson LA, Fici GJ. Lund JE, Boyle TP. Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76.
45. Eitzman DT, McCoy RD, Zheng X, Fay WP. Shen T & Ginsburg D. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996: 97: 232-237.
46. Heckel JL, Sandgren EP, Degen, JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456.
47. Sidenius N. Expression of the aminoterminal fragment of urokinase-type plasminogen activator in transgenic mice. PhD. thesis, University of Copenhagen, Denmark, 1993.
48. Carmeliet P, Schoonjans L. Kicckens L. Ream B, Degen J, Bronson R. De Vos R, van den Oord JJ, Collen D, Mulligan R. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
49. Carmeliet P, De Clercq C. Janssen S. Pollefeyt S, Bouché A. Wijns S. Mulligan RC. Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995: 748P: 367-381.
50. Bugge TH. Flick MJ, Danton MJ. Daugherty CC, Romer J, Dano K. Carmeliet P. Collen D & Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sc.USA (in press).
51. Carmeliet P. Kieckcns L, Schoonjans L, Ream B. Van Nuffelen A, Prendergast G. Cole M. Bronson R, Collen D. Mulligan RC. Plasminogen activator inhibitor-1 gene deficient mice. 1. Generation by homologous recombination and characterization. J Clin Invest 1993: 92: 2746-2755.
52. Carmeliet P. Stassen JM. Schoonjans L. Ream B, van den Oord JJ. De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 1993: 92: 2756-2760.
53. Dewerchin, M. Van Nuffelen, Wallays G, Bouche A. Moons L, Carmeliet P, Mulligan RCM, Collen D. Generation and characterization of urokinase receptor deficient mice.J Clin Invest 1996; 97. 870-878.
54. Bugge TH, Suh TT. Flick MJ, Daugherty CC. Romer J, Solberg H, Ellis V. Dano K. Degen JL. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertililly. J Biol Chem 1995: 270: 16886-16894.
55. Ploplis V. Carmeliet P. Vazirzadeh S. Van Vlaenderen I. Moons L. Plow E. Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation 1995: 92: 2585-2593.
56. Bugge TH. Flick MJ, Daugherty CC & Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Development 1995: 9: 794-807.
57. Dougherty K, Yang A, Harris J. Saunders T, Camper S & Ginsburg D. Targeted deletion of the murine plasminogen activator inhibitor-2 gene by homologous recombination. Blood 1995; suppl I. 86:455a.
58. Zheng X. Saunders TL. Camper SA. Samuelson LC & Ginsburg D. Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci 1995; 92: 12426-12430.
59. Umans L, Semecls L, Overbergh L, Lorent K, Van Leuven F & Van den Berghe H. Targeted inactivation of the mouse alpha2-macroglobulin gene. J Biol Chem 1995: 270:19778-19785.
60. Herz J, Clouthier DE. Hammer RE. LDL receptor-related protein internalizes and degrades uPA:PAl-l complexes and is essential for embryo implantation. Cell 1992; 71:411-421.
61. Richards W.G. Carroll P.M. Kinloch R.A. Wassarman P.M. Strickland S. Creating maternal effect mutations in transgenic mice: antisense inhibition of an oocyte gene product. Develop Biol 1993; 160: 543-553.
62. Leonardsson G. Peng XR. Liu K, Nordstrom L. Carmeliet P. Mulligan R, Collen D & Ny T. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci USA 1995: 92: 12446-12500.
63. Cui J, Saunders TL & Ginsburg D. Analysis of factor V function by gene targeting in embryonic stem cells. Blood 1995: suppl 1: 86: 449a.
64. Bi L, Lawler AM. Antonarakis SE. High KA. Gearhart JD & Kazazaian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-121.
65. Montgomery RR & Scott JR Hemostasis: diseases of the fluid phases. In: Haematology of infancy and childhood. Eds. Nathan GD & Oski FA. Saunders WB Co. Philadelphia, PA. 1993: 1605-1650.
66. Al-Mondhiry H & Ehmann WC. Congenital afibrinogenemia. Am J Hematol 1994; 46: 343-347.
67. White GC. Coagulation factors V and VIII: normal function and clinical disorders. (1995) In: Blood. Principles & Practice of hematology. Eds: Handin RI. Lux SE. Stossel TP (JB Lippincott Co. Philadelphia); pp 1151-1180.
68. Fay WP. Shapiro AD. Shih JL, Schleef RR. Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type I due to a framcshift mutation. N Engl J Med 1992: 327: 1729-1733.
69. Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Reviews 1989; 3: 11-17.
70. Elliott MJ. Faulkner-Jones BE, Stanton H. Hamilton JA, Metcalf D. Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. J Immunol 1992: 149: 3678-3681.
71. Kluft C. Dooijewaard G. Emeis JJ. Role of the contact system in fibrinolysis. Sem. Thromb. Hemost. 1987; 13: 50-68.
72. Plow EF. Edgington TS. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 1975; 56: 30-38.
73. Hamsten A, de Faire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9
74. Robbins KC. Dysplasminogencmias. Enzyme 1988: 40: 70-78.
75. Liu AC and Lawn RM. Lipoprotein(a) and atherogenesis. Trends Cardiovasc Medicine 1994; 4:40-44.
76. Palabrica TM. Liu AC. Aronowitz MJ, Furie B. Lawn RM & Furie BC. Antifibrinolytic activity of apolipoprotein (a) in vivo: human apolipoprotein (a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Medicine 1995; 1: 256-259.
77. Forrester JS. Fishbein M. Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769.
78. Libby, P. Schwartz, D. Brogi, E. Tanaka, H. and Clinton, S.K. A cascade model for restenosis. A special case of atherosclerotic progression. Circulation 1992: 86 (suppl.III), 111 47-52.
79. Clowes, A.W. and Reidy, M.A. Prevention of stenosis after vascular reconstruction: pharmacologic control of intima hyperplasia-A review. J. Vase. Surgery 1991: 13, 885-891.
80. Simpson AJ. Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAL 1) in tissues. J Clin Pathol 1991:44: 139-143.
81. Clowes AW. Clowes MM. An YPT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ. Res 1990; 67: 61-67.
82. Jackson CL. Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992: 667: 141-150.
83. Jackson CL. Raines EW, Ross R. Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscl Throtnb 1993; 13:1218-1226.
84. Sawa H. Fujii S. Sobel BE. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arterioscler Thromb 1992; 12: 1507-1515.
85. Carmeliet, R, and Collen, D. Physiological consequences of over-or under-expression of fibrinolytic system components in transgenic mice. In: Vascular control of hemostasis; Advances of Vascular Biology (Vadas M and Harlan J. eds) (in press).
86. Herbert JM, Lamarche I. Prabonnaud V. Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269:3076-3080.
87. Carmeliet P. Stassen JM. Dcclercq C. Kockx M. Moons L. Collen D. A model for arterial neoin-tima formation using perivascular electric injury in mice, (submitted).
88. Carmeliet P, Moons L, Dewerchin M, Stassen JM, Dcclercq C, Gerard R. Collen D. Receptor-independent role of urokinase-type plasminogen activator in arterial neointima formation in mice, (submitted)
89. Carmeliet P, Moons L, Van Vlaenderen I, Ploplis V, Plow EF, Collen D. Role of plasmin proteolysis in arterial neointima formation in mice (submitted).
90. Yu HR and Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine BI6 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990: 50: 7623-7633.
91. Wilhelm O. Weidle U. Hohl S. Rettenberger P. Schmitt M. Gracff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator. Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett, 1994; 337: 131-134.
92. Lee SW. Kahn ML, Dichek DA. Expression of an anchored urokinase in the apical endothelial cell membrane. J. Biol. Chem. 1992: 267: 13020-13029.
93. Stephens RW, Bokman AM, Myohanen HT. Reisberg T, Tapiovaara H, Pedersen N, Grondahl-Hansen J, Llinas M, Vaheri A. Heparin binding to the urokinase kringle domain. Biochemistry 1992:31: 7572-7579.
94. Hamsten A and Eriksson P. Fibrinolysis and Atherosclerosis: and update. Fibrinolysis 1994; 8(Suppl 1): 253-262
95. Juhan-Vague I. Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438.
96. Schneiderman J. Sawdey MS, Keeton MR. Bordin GM. Bernstein EF. Dilley RB. Loskutoff. DJ Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nall Acad. Sci. USA 1992; 89: 6998-7002.
97. Schneiderman J. Bordin GM. Engelberg I, Adar R. Seiffert D. Thinnes T. Bernstein EF. Dilley RB. Loskutoff DJ. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall. A possible mechanism for aneurysm expansion. J. Clin. Invest. 1995; 96: 639-645.
98. Lupu F, Heim DA. Bachmann F, Humi M, Kakkar VV. Kruithof EKO. Plasminogen activator expression in human atherosclerotic lesions. Arterioscler. Thromb. Vase. Biol. 1995: 15: 1444-1455.
99. Grainger DJ. Kemp PR, Liu AC. Lawn RM and Metcalfe JM. Activation of transforming growth factor-B is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-462.
100. Bcrtozzi P. Astedl B. Zenzius L, Lynch K. LeMaire F, Zapoli W. Chapman HA. Depressed bronchioalveolar urokinase activity in patients with adult respiratory distress syndrome. New Engl J Med 1990: 322:890-897.
101. Tomooka S, Border WA. Marshall BC, Noble NA. Glomerular matrix accumulation in liked to inhibition of the plasmin protease system. Kidney Internat 1992: 42:1462-1469.
102. Kitching R, Carmeliet P. Ploplis V. Collen D, Plow E. Holdsworth ER & Tipping P. Glomerulonephritis in mice with genetic deficiencies of the plasminogen system. XIIth International Congress on Fibrinolysis and thrombolysis, Barcelona, June 24-28. 1996. Fibrinolysis Suppl.
103. Barazzone C. Bclin D, Huarte J. Vassalli JD & Sappino AP. Deleterious role of plasminogen activator inhibitor-1 in response to hyperoxia in mouse. 1996 International Conference. New Orleans, Louisiana
104. Romer J. Bugge TH, Pyke C. Lund LR, Flick MJ. Dcgen JL & Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Medicine 1996; 2: 287-292.
105. Leloup G, Lemoine P. Carmeliet P. Vaes G. Bone resorption and response to parathyroid hormone or 1,25 dihyroxyvitamin D3 in fetal metatarsals and calvariae from transgenic mice devoid of tissue or urokinase type plasminogen activator or of their inhibitor. PAI-1. Twenty fourth European Symposium on Calcified Tissues. May 1995, Aarhus, Denmark. Calcified Tissue International (abstract).
106. Bouillon R. Van Herck E. Vcrhaeghe J. Carmeliet P. Bone metabolism in transgenic mice, deficient in tissue type plasminogen activator. Xth International Congress on Calcium regulatory hormones. February 1995, Melbourne, Australia. Bone and Mineral (abstract)